# OnCo record tregzi (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tregzi/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tregzi" ;
  schema:name "Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq"@en ;
  schema:alternateName "Orca-T"@en, "Tregzi"@en, "Tregzi" ;
  schema:description "Tregzi, formerly Orca-T, is a donor stem cell transplant sorted with high precision and given with regulatory T cells, so that patients with blood cancers keep the graft's anti-cancer effect while being protected from chronic graft-versus-host disease. The FDA approved it on 30 June 2026 for adults having a matched-donor transplant."@en ;
  schema:url <https://onco.cc/drugs/tregzi/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched>, <https://clinicaltrials.gov/study/NCT05316701> ;
  onco:status "approved" ;
  onco:modality "Precision-sorted allogeneic stem cell graft with regulatory T cells" ;
  onco:approval "US 2026: Adults with haematological malignancies undergoing matched-donor haematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease-free survival" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/mds/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:companies <https://onco.cc/companies/orca-bio/> ;
  onco:trials <https://onco.cc/trials/nct05316701/> .